Table 3 Incidence rates according to exposure to DAA treatment for HCC, all-cause mortality, and liver transplant in all 55 patients with a Meld score > 20 or Child–Pugh score C
Not exposed to DAA N = 12 | Exposed to DAA N = 43 | P-value | |||
|---|---|---|---|---|---|
n/pyr | Incidence/100pyrs (95% CI) | n/pyr | Incidence/100pyrs (95% CI) | ||
HCC (N = 11) | 7/22 | 31.2 (12.5–64.3) | 4/100 | 4.0 (1.1–10.3) | 0.001 |
All-cause mortality (N = 20) | 10/26 | 38.5 (18.5–70.8) | 10/112 | 9.0 (4.3–16.5) | 0.002 |
Liver related mortality (N = 13) | 6/26 | 23.1 (8.5–50.2) | 7/112 | 6.3 (2.5–12.9) | 0.026 |
Non-liver related mortality (N = 5) | 2/26 | 7.7 (0.9–27.8) | 3/112 | 2.7 (0.6–7.9) | 0.275 |
Liver transplant (N = 9) | 4/20 | 20.0(5.5–51.3) | 5/92 | 5.4 (1.8–12.7) | 0.07 |